Dr Mary Speir

Senior Research Scientist

BSc Hons; PhD

Mary has built her career in medical science research in world-leading organisations, including Boston Children’s Hospital / Harvard Medical School, Monash University and Hudson Institute of Medical Research.

Her background is in programmed cell death and she has highly relevant experience in infectious and inflammatory disease. She joined Noxopharm in 2021 as a Senior Research Scientist, where she leads the Noxopharm / Pharmorage in vivo research related to autoimmune diseases and mRNA vaccines.

Mary maintains a position at Hudson Institute as an Honorary Research Associate with the Cell Death and Inflammatory Signalling group. She works closely with Associate Professor Michael Gantier’s team there and acts as a valuable link between Hudson Institute and Noxopharm / Pharmorage. Her work contributes to the scientific progress being made in the development and discovery of new anti-inflammatory drugs for a range of diseases.

Mary has a PhD from Monash University and a Bachelor of Science with Honours (1st class) from the University of Otago (Te Whare Wānanga o Otāgo).